The contract testing, development, and manufacturing organization (CDMO) announced the finished expansion at Interphex last week in New York.
The expanded facility features an additional 4,200 square feet of space to house a new microbiology laboratory and a modular cleanroom area, which features isolator technology and an ISO 6 cleanroom for sterility testing.
The site, formally Microtest Labs, has “an extensive client base through historical testing services as well as expanded services since being acquired by Avista Pharma,” Patrick Walsh, CEO of Avista Pharma, told us.
“We believe that continued investments in facility renovations, equipment, and services at this facility are important to maintain best-in-class service levels,” he added.
Walsh further explained the new service offerings were requested by clients and the facility expansion “is necessary to keep pace with our intended growth targets.”
Additional capabilities include isolator sterility testing, which enables Avista to provide sterility testing with comprehensive evaluations and a lower risk of false positives.
“This capability complements the services that we provide and is particularly sought by manufacturers such as parenteral pharmaceutical manufacturing clients,” Walsh added.
Facility improvements also include a new microbiology laboratory and support area with new autoclaves and glassware washers.
“We continue to invest in our existing service offerings and to rapidly expand new offerings,” Walsh explained.
In addition to the expansion at its Agawam, MA facility, Avista is currently making investments at other Avista Pharma facilities, including increased scale of API manufacturing and solid dose finished product manufacturing at its Longmont, CO facility.